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Abstract
Background: A wide spectrum of clinical manifestations and immune responses exist in canine L. infantum
infection. Ibizan hounds are more “resistant” to disease than other dog breeds. Recognition of pathogen-associated
molecule patterns by toll like receptors (TLRs) rapidly triggers a variety of anti-microbial immune responses through
the induction of pro-inflammatory cytokines such as TNF-α and IL-6 which may play an important role in
controlling Leishmania infection. The main objective of this study was to investigate and compare the effect of a
TLR2 agonist (TLR2a) alone or in combination with L. infantum antigen (LSA) on ex vivo whole blood cytokine production
from healthy seronegative IFN-γ non-producer dogs from an area of low in canine leishmaniosis endemicity (n= 11); sick
seropositive dogs with low production of IFN-γ (n= 17) and healthy seronegative or low positive Ibizan hounds with a
predominant IFN-γ production (n= 21) from a highly endemic area. Whole blood was stimulated with medium alone (Ø),
LSA, concanavalin A, TLR2 (Pam3CSK4) receptor agonist (Ø + TLR2a) and TLR2a and LSA (LSA + TLR2a) for 48 h.
Supernatants were harvested for measurement of canine TNF-α and IL-6 cytokines by ELISA.
Results: A significant increase of TNF-α was found in the supernatants of stimulated blood from all groups (Ø + TLR2a and
LSA + TLR2a) when compared with medium alone. A similar pattern was observed for IL-6. Interestingly, a significant
increase of TNF-α production was only observed when stimulation with LSA + TLR2a was compared with TLR2a alone in
Ibizan hounds. A significant increase of TNF-α production was observed with stimulation of LSA + TLR2a when compared
with LSA in all groups. Significantly higher concentrations of TNF-α and IL-6 were detected in Ibizan hounds, especially for
the Ø + TLR2a and LSA + TLR2a treatments compared with other groups.
Conclusions: This study demonstrated that TLR2a alone enhances the production of the inflammatory cytokines TNF-α
and IL-6 in sick, “resistant” and healthy non-infected dogs. In addition, a combination of LSA+TLR2a promoted a synergistic
pro-inflammatory effect with TNF-α in Ibizan hounds but not in seropositive sick dogs and seronegative healthy dogs.
These findings might suggest the importance of Pam3CSK4 as a possible immunomodulator for CanL.
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Background
Canine leishmaniosis (CanL) due to L. infantum is a life-
threatening sand fly-borne zoonotic disease with a wide dis-
tribution in Central and South America, Asia, Africa and
the Mediterranean basin regions [1]. The seroprevalence for
leishmaniosis reported in dogs in the Mediterranean basin
ranges from 5 to 30% depending on the region [2]. A broad
range of immune responses and several degrees of disease
have been described for CanL ranging in severity from a
chronic subclinical infection, a self-limiting disease, to non-
self-limiting illness, determining the prognosis and treat-
ment options [2, 3]. Therefore, a clinical staging system of
this disease is currently used in the clinical setting [2].
The immune responses mounted by dogs at the time of
infection and thereafter appear to be the most important
factor in determining whether and when the infection will
progress from a subclinical state into clinical illness [4].
Dogs that are able to control infection by either resolving
it and eliminating the parasite or restricting the infection
and remaining consistently subclinical are considered clin-
ically “resistant” [3]. As an example, Ibizan hounds appear
to be more “resistant” than other more susceptible dog
breeds and rarely develop clinical signs related with L.
infantum infection [5–7]. Therefore, this breed provides
an interesting model to study the origin of this kind of ap-
parently immunological resistance. In contrast, dog breeds
that are predisposed to developing a disseminated infec-
tion and progressing towards clinical CanL are considered
susceptible (e.g., Boxer, Cocker Spaniel, Rottweiler and
German Shepherd) [7].
The ability of the host to control L. infantum infection
requires the generation of cellular mediated immune
(CMI) responses, which activate host infected macro-
phages in order to kill intracellular Leishmania parasites
[8]. CMI protection is given by the activation of CD4+ T
helper cells (Th) from the adaptive immunity, which is
influenced by a mixed response due to the balance
between Th1-like lymphocytes (Th1) and Th2-like lym-
phocytes (Th2) [8]. Classically, the polarized Th1/Th2
(pro-inflammatory/anti-inflammatory) response against
Leishmania infection was associated with rodent models
[9]. On the other hand, humans and dogs seem to de-
velop a more intricate and complex immune response.
Previous studies performed on peripheral blood samples
from Leishmania-infected dogs described a protective
induction of a predominant Th1 response that was asso-
ciated with the activation of cells, producing IFN-γ, IL-2
and TNF-α, that was correlated with immunity and heal-
ing [10]. After activation mediated by IFN-γ, macro-
phages produce TNF-α that increases reactive oxygen
substances (ROS) in peripheral blood mononuclear cells
(PBMCs) from dogs with leishmaniosis leading
Leishmania destruction [11]. This T-cell activation con-
stitutes the cornerstone and the link with the innate
immune system, especially represented by macrophages,
dendritic cells (DCs) and neutrophils [12].
The family of toll like receptors (TLRs) are trans-
membrane proteins expressed mainly in macrophages,
DCs, natural killer (NK) cells and lymphocytes (T and
B); they are specialized in mediating the innate recogni-
tion of pathogens associated molecules patterns
(PAMPs), that are presented in a huge range of patho-
gens of clinical and immunological relevance [13] and
rarely found in the host cells [14, 15]. Recognition of
each PAMP appears to be associated to distinct TLRs.
Once the response is set, the activation of specific sig-
naling pathways [16] rapidly triggers a variety of phe-
nomena that amplify parasite immune responses by
stimulating the production of pro- inflammatory cyto-
kines, which may play an important role in controlling
Leishmania infection [17]. TLR2 was shown to recognize
ligands such as lipopeptides [18], peptidoglycans [19] and
external proteins [20], among others. As soon as TLR2 is
linked to its ligands, the induction of intracellular path-
ways such as MyD88 activates nuclear factor (NF)-kB pro-
moting the secretion of pro- and anti-inflammatory
cytokines. Published studies that contribute to the know-
ledge of TLR2 in Leishmania infection are limited [21]. A
protective role during infection was proposed for TLR2 as
one of the molecules involved in Leishmania phagocytosis
[22]. As another example, an experimental mouse model
study using TLR2 agonist (Pam3CSK4) has demonstrated
protection against Leishmania infection [23].
Currently, treatments are not always effective against
the disease and a development of long-lasting vaccine
would be a cornerstone in the prevention of disease.
Therefore, it is important to discover new immunomod-
ulators for prevention and treatment of this important
canine zoonotic infectious disease. Based on previous
published findings, the hypothesis of this study was that
TLR2 agonist alone will enhance the production of in-
flammatory cytokines in canine ex vivo whole blood. In
addition, we hypothesized that the combination TLR2
agonist with L. infantum soluble antigen might promote
a synergistic release of pro-inflammatory cytokines when
compared with L. infantum antigen or TLR2 ligand
alone in previously L. infantum-infected dogs. Therefore,
the main objective of this study was to investigate and
compare the effect of a TLR2 agonist (TLR2a) alone or
in combination with L. infantum antigen on ex vivo
whole blood cytokines production from dogs in different
stages of infection (seropositive sick, “resistant” (Ibizan
hounds) and seronegative clinically healthy dogs).
Methods
Dogs and sampling
The dogs enrolled in the study were from different
Catalonian and Balearic Islands veterinary centers in
Martínez-Orellana et al. Parasites & Vectors  (2017) 10:123 Page 2 of 7
Spain and were divided into three groups: Group 1:
17 dogs with clinical leishmaniosis from Fundació
Hospital Clínic Veterinari (Bellaterra, Barcelona) and
Hospital Ars Veterinaria (Barcelona); Group 2: 21
healthy Ibizan hound from a highly endemic area of
CanL (the Island of Mallorca, Spain) [5]; and Group
3: 11 clinically healthy dogs from a low-endemicity
area [24] (Asturias, Spain) with no travel history out-
side Asturias. The diagnosis of CanL was made based
on the results of the physical examination, a complete
blood count using System Siemens Advia 120 (Sie-
mens Healthcare GmbH, Germany), a biochemical
profile including creatinine, urea, total proteins, ALT
and total cholesterol measured by the Olympus
Analyzer AU 400 (Olympus, Center Valley, USA),
protein serum electrophoresis by Hydrasys® (Sebia
Electrophoresis, Lisses, France), urinalysis with urinary
protein/creatinine ratio (UPC) and quantitative
serology for the detection of L. infantum-specific
antibodies by means of a serial dilution in house
ELISA [25]. Cytological evaluation of any lesion or
cutaneous histology and/or immunohistochemistry for
Leishmania was also performed as described else-
where in some cases when needed [26]. In addition,
blood DNA extraction and L. infantum real-time PCR
(RT-PCR) were performed as previously described
[25]. Dogs were classified in four clinical stages (I,
mild disease; II, moderate disease; III, severe disease;
and IV, very severe disease) at the time of diagnosis
as previously described [2].
Whole blood cytokine release assay
Heparinized whole blood cytokine release assay was per-
formed as previously described [27] with some modifica-
tions. Briefly, five different treatment conditions were
established: (i) medium alone (Ø); (ii) medium with sol-
uble L. infantum antigen (LSA) at a concentration of
10 μg/ml provided by Dr. Cristina Riera (L. infantum
antigen 5 mg/ml, Facultat de Farmacia, Universitat de
Barcelona); (iii) medium with mitogen concanavalin A
(ConA, 100 mg Medicago® Uppsala, Sweden) at a con-
centration of 10 μg/ml; (iv) medium with TLR2 receptor
agonist (Ø + TLR2a) at a concentration of 300 ng/ml
(Pam3CSK4 1 mg/mL Invivogen® San Diego, California);
and (v) medium with TLR2 receptor agonist at concen-
tration of 300 ng/ml and soluble L. infantum antigen
(LSA+TLR2a) at a concentration of 10 μg/ml. The plates
were incubated at 37 °C in 5% of CO2 air. Then, blood
was centrifuged at 300× g for 10 min and the super-
natant was collected and stored at −80 °C until used.
TNF-α and IL-6 concentrations were measured in super-
natants from 48 h. IFN-γ was measured in supernatants
from 5 days after stimulation with ConA and LSA or
medium alone as previously described [27].
Sandwich ELISA for canine cytokines
Cytokine analysis of IFN-γ, TNF-α, and IL-6 was per-
formed according to the manufacturer’s instructions
(DuoSet® ELISA by Development System R&DTM,
Abingdon, UK) using 96-well cell plate flat bottom
(Costar ® Corning, NY, USA). Slight modifications were
done for the IFN-γ ELISA as described elsewhere [27].
Standard curve for TNF-α started with 1000 pg/ml and
two-fold dilutions were made until 7.8 pg/ml concentra-
tion. Finally, standard curve for IL-6 starting with
4000 pg/ml and two-fold dilutions were made until
31.2 pg/ml concentration. Each cytokine concentration
for all treatment conditions studied was analyzed after
substracting medium alone for comparison between
groups. Dogs were classified as IFN-γ producers and
non-producers as previously described [27].
Statistical analysis
The statistical analysis was performed using the SPSS 22.0
software for Windows (SPSS Inc., USA). A non-parametric
Mann-Whitney U-test was used to compare groups. A non-
parametric Wilcoxon signed-rank test was used to compare
paired continuous variables. Differences were considered
significant with a 5% significance level (P < 0.05). Graphs
were performed using excel GraphPad Prism 7 (GraphPad
Software, La Jolla, CA, USA).
Results
Clinical data
All 11 clinically healthy dogs from a low-endemic area
of CanL (Group 3) were seronegative. There were five
females (three spayed and two intact) and six males
(three neutered and three intact) with a median of age of
49 months and an age range from 17 months to 12 years.
Seven were purebred and four mixed breed.
The median of age of 21 clinically healthy Ibizan hounds
(Group 2) was 27 months with a range from seven months
to five years. Four males and 17 females were studied. In
addition, all Ibizan hounds studied were seronegative with
the exception of two dogs that were low positive.
Dogs with clinical leishmaniosis (Group 1), five females
and 12 males, were mainly purebred (n = 14) and only
three were mixed breed. The median age at the time of
diagnosis was 79 months with a range from eight months
to 17 years. All sick dogs presented at the time of diagno-
sis several typical clinical signs of leishmaniosis. Dogs were
classified in the following clinical stages [2, 28]: II-
moderate disease (stage IIa, n = 4 and stage IIb, n = 3); III-
severe disease (n = 7); and IV-very severe disease (n = 3).
Antibody levels and parasite specific IFN-γ production in
all groups studied
The results of IFN-γ concentrations for each condition are
shown in Fig. 1. Clinically healthy dogs from Asturias
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(Group 3: mean ± SD: 13.3 ± 5.7 EU; Mann-Whitney U-test:
Z = -4.39, P = 0.0001) and Mallorca (Group 2: 16.6 ± 14.2
EU; Mann-Whitney U-test: Z= -5.24, P = 0.0001) presented
statistically significant lower levels of antibodies than dogs
with clinical leishmaniosis (Group 1: 22,747.1 ± 33,756.4
EU), respectively. No statistically significant differences were
found when both clinically healthy groups were compared.
In general, healthy control dogs from the low endem-
icity area (Group 3) did not response to IFN-γ after LSA
stimulation. Two out of 17 dogs with clinical leishmanio-
sis were classified as IFN-γ producers and further classi-
fied as being in stage IIa. The majority of the dogs were
classified as IFN-γ non-producers (88%). The clinical sta-
ging of these dogs was: two dogs in stage IIa (13.3%), two
dogs in stage IIb (13.3%), eight dogs in stage III (53.3%)
and three dogs in stage IV (20%). Only two Ibizan hounds
did not respond to IFN-γ after LSA stimulation, the rest
of the dogs (90%) responded at high levels.
Whole blood TNF-α release assay
The results of TNF-α concentration from the three groups
of dogs studied for each condition are shown in Fig. 2a
and Additional file 1. An additional file shows statistical
differences (see Additional file 1). The most important
finding was the significant higher production of TNF-α
after stimulation with ConA, Ø + TLR2a, LSA + TLR2a
when compared with medium alone in the three groups
studied. Interestingly, only Ibizan hounds produced sig-
nificantly higher levels of TNF-α after stimulation with
LSA when compared with medium alone. Furthermore,
Ø + TLR2a and LSA +TLR2a elicited higher production
of TNF-α than LSA alone in all three groups studied. No
significant differences were found in TNF-α concentra-
tions when comparing Ø +TLR2a stimulated blood and
LSA +TLR2a in sick (Group 1) and control (Group 3)
dogs while stimulated blood from Ibizan hounds (Group
2) showed statistically significant lower TNF-α production
on Ø +TLR2a when compared with LSA + TLR2a.
No significant differences were found when control
healthy dogs of Group 3 were compared with sick dogs
in all conditions studied. In contrast, Ibizan hounds
(Group 2) secreted significantly higher levels of TNF-α
than control dogs (Group 3) and sick dogs (Group 1)
after Ø + TLR2a and LSA + TLR2a.
Fig. 1 IFN-γ concentrations after whole blood stimulation with LSA and ConA in all groups studied. Sick dogs (Group 1), Ibizan hounds (Group 2)
and healthy controls (Group 3). a LSA: Group 2 > Group 3 (Mann-Whitney U-test: Z = -4.15, P = 0.0001); Group 2 > Group 1 (Mann-Whitney U-test:
Z = - 4.53, P = 0.0001). b ConA: Group 2 > Group 1 (Mann-Whitney U-test: Z = -4.15, P = 0.0001) and Group 3 > Group 1 (Mann-Whitney U-test:
Z = -3.68, P = 0.0001)
Fig. 2 a TNF-α and b IL-6 concentrations from the three groups of dogs studied after each condition. Sick dogs (Group 1), Ibizan hounds (Group
2) and healthy controls (Group 3). An additional file shows statistics (see Additional file 1). Panels: Medium alone (Ø), soluble L. infantum antigen
(LSA), concanavalin A (ConA), TLR2 (Pam3CSK4) receptor agonist (Ø+TLR2a) and TLR2a and LSA (LSA+TLR2a)
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Whole blood IL-6 release assay
The results of IL-6 concentration in all groups studied
after each condition are shown in Fig. 2b and Additional
file 1. An additional file shows statistical differences (see
Additional file 1). The healthy control (Group 3) did not
present any significant differences within treatments in
IL-6 secretion. The sick dogs (Group 1) and Ibizan
hounds (Group 2) presented significantly lower concen-
trations of IL-6 in medium alone when compared with
Ø + TLR2a and LSA + TLR2a stimulation. In addition,
Ø + TLR2a and LSA + TLR2a elicited significantly higher
stimulation of IL-6 than LSA alone in Groups 1 and 2.
There was no statistically significant difference in IL-6
production within Ø + TLR2a and LSA + TLR2a in the
sick dogs (Group 1) and Ibizan hounds (Group 2). Ibizan
hounds (Group 2) secreted significantly higher levels of
IL-6 than control dogs (Group 3) and sick dogs (Group 1),
after Ø + TLR2a and LSA +TLR2a.
Discussion
Pam3CSK4 is a synthetic derivative of triacylated lipo-
proteins that conserves most of the immune stimulatory
activity of full-length lipoproteins [29]. Here, we ex-
plored the impact of the lipopeptide Pam3CSK4 in
whole blood from dogs. To the best of our knowledge,
the findings of the present study give new insights, for
the first time, on the inflammatory effects that, the
Pam3CSK4 TLR2 agonist alone or in combination with
L. infantum antigen, induce in ex vivo whole blood dogs
in different stages of Leishmania infection (sick, “resist-
ant” and non-infected healthy dogs).
Our findings demonstrate that the Pam3CSK4 TLR2
agonist alone significantly increased the production of
TNF-α as previously described [30, 31]. In agreement
with the present study, stimulation of purified canine
polymorphmononuclear cells (PMNs) with lipoteichoic
acid, a ligand of TLR2, promoted the release of pro-
inflammatory chemokine IL-8 [32]. In this study, the
Pam3CSK4 TLR2 agonist alone also significantly in-
creased the production of IL-6. The main cell sources of
cytokine production after stimulation with a TLR2 agon-
ist in the present study are likely to be granulocytes and
monocytes due to the fact that granulocyte is the pre-
dominant inflammatory nucleated cell in whole blood in
canines [33]. In addition, it has been also demonstrated
that TLR2 protein is easily detectable by flow cytometry
on the canine peripheral blood granulocyte and mono-
cyte cell surfaces and less strongly in lymphocytes [32].
This is similar to findings in humans where lymphocytes
do not express TLR2 in unstimulated blood [34]. This
study corroborates the pro-inflammatory effect that the
Pam3CSK4 TLR2 agonist has in canines.
A significant strong activation of a pro-inflammatory
response was observed in dogs studied with high levels
of TNF-α and IL-6 after TLR2a blood stimulation. How-
ever, significantly stronger TNF-α and IL-6 responses
after TLR2a blood stimulation were observed in Ibizan
hounds when compared with sick and control dogs. The
relation of TLR2 and TLR4 in pro- and anti-inflammatory
cytokine production was previously investigated in human
patients with visceral leishmaniasis (VL). Gatto et al. [35]
stimulated PBMCs from cases of VL with TLR2 and TLR4
agonists and later cytokine production and nitric oxide
(NO) was evaluated. In agreement with the present study,
they also described higher levels of TNF-α in patients with
visceral leishmaniosis after stimulation with TLR2 or
TLR4 agonists [35]. In addition, analysis of the involve-
ment of TLR2 and TLR4 agonists in NO production dem-
onstrated that these two receptors appeared to be
involved in NO production.
Interestingly, a significant increase of TNF-α produc-
tion was observed when whole blood from Ibizan
hounds was stimulated with a combination of L. infan-
tum antigen and TLR2 agonist when compared with L.
infantum antigen alone and TLR2 agonist alone suggest-
ing a synergistic pro-inflammatory effect. It is likely that
this synergistic pro-inflammatory effect is due to the
TNF-α release by granulocytes and monocytes and to
less extent to activated or memory T lymphocytes as de-
scribed in humans [36]. TLR2 is expressed in human ac-
tivated T cells as a costimulatory receptor and memory
T cells [36]. Thus, human TLR2 serves as a costimula-
tory receptor for antigen-specific T cell development and
participates in the maintenance of T cell memory and it
is likely that the same process occurs in canines. This
suggests that pathogens, via their pathogen-associated
molecular patterns, may contribute directly to the per-
petuation and activation of long-term T cell memory in
both antigen-dependent and independent manners.
These findings are similar to the ones documented by
combinations of TLR4 or TLR7 agonists and vaccine an-
tigens leading to a more robust Th1 CD4+ T cell re-
sponses from sub-clinically infected dogs [37].
Therefore, based on the present findings, Pam3CSK4
TLR2 agonist might be used as an adjuvant in future
vaccine development having an impact on controlling
this infection.
Furthermore, although the data presented here result
from an ex-vivo study in dogs and murine models as
well as L. donovani or L. major strains are very different
from canine L. infantum infection [38], when susceptible
and “resistant” mice were immunized with live L. major
in the presence of Pam3CSK4 (TLR2 agonist), it was
found that the development of skin lesion in both
groups of animals were prevented but at different mag-
nitudes [23]. Once again in another murine study, TLR2
seemed to have an active role in the control of cutane-
ous leishmaniosis since TLR2-deficient mice presented
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an exacerbation of the pathology and parasitemia
through promotion of the Th2 immunity in L. major
and Leishmania mexicana infections [39]. However, it is
important to highlight that TLR2/6 ligand Pam2CSK4 is
a Th2 polarizing adjuvant in L. major and Brugia malayi
murine vaccine models [40]. In addition, in a canine
study, a L111f vaccine antigen containing a LeIF, a TLR2
agonist glycoprotein produced Th2 skewed responses
leading to less robust CD4+ T cell population responses
[37]. Further research needs to be carried out to better
elucidate the findings of this study. It is important to
highlight that activation of TLR receptors by specific ag-
onists as in the case of Pam3CSK4 TLR2 agonist could
be a powerful tool in the control and treatment of the
CanL, either as adjuvant in future vaccine development
or during treatment as immunomodulator to control
infection in sick dogs. The use of TLR2 agonist in com-
bination with conventional treatment (meglumine anti-
moniate or miltefosine + allopurinol) [2] might allow
reduction of the anti-Leishmania drug dose or shorten-
ing the length of conventional treatment avoiding long
term side effects [41] and drug resistance [42].
Ibizan hounds are considered a more “resistant” breed
to L. infantum infection due to the presence of a pro-
tective immune response that is associated with a clinic-
ally healthy status and good outcome [2, 5, 43]. Data
presented here showed a marked IFN-γ response to LSA
after blood stimulation in Ibizan hounds when compared
with control and sick dog groups. In this study, an over-
all seronegative result seen in Ibizan hounds in combin-
ation with a high production of specific L. infantum
IFN-γ and TNF-α corroborates the previous findings
demonstrating a predominance of L. infantum specific
cellular immunity by means of leishmanin skin test in
Ibizan hounds living in a highly endemic area of leish-
maniosis [5].
Taking these findings into account, the Ibizan hound
is an excellent canine breed model for the study of the
protective anti-Leishmania immune response and for
comparison to sick and control healthy dogs in endemic
areas as well as to other “resistant” animal models.
Conclusions
This study demonstrated that TLR2a alone enhances the
production of the inflammatory cytokines TNF-α and
IL-6 in sick, “resistant” and healthy non-infected dogs.
In addition, a combination of LSA+TLR2a promoted a
synergistic pro-inflammatory effect with TNF-α in Ibizan
hounds but not in seropositive sick dogs and seronega-
tive healthy dogs. These findings might suggest the im-
portance of Pam3CSK4 as a possible immunomodulator
for CanL either as an adjuvant for a future vaccine de-
velopment or as immunotherapy in dogs with clinical
illness.
Additional file
Additional file 1: Statistical differences in TNF-α and IL-6 concentrations
for conditions and among groups studied. (DOC 28 kb)
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